The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH

Endocrinology

Volumn 140, Issue 11, 1999, Pages 5066-5074

  Gaylinn, Bruce D ^a   DeAlmeida, Venita I ^b   Lyons Jr , Charles E ^a   Wu, Kenneth C ^b   Mayo, Kelly E ^b   Thorner, Michael O ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HORMONE DEFICIENCY; HORMONE RECEPTOR INTERACTION; HYPOPITUITARISM; LIGAND BINDING; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE;

EID: 0033303550     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.11.7092     Document Type: Article

References (51)

1. Growth hormone releasing hormone
2. Growth hormone-releasing hormone
3. Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6
4. Etiology of growth hormone deficiency in little, Ames and Snell dwarf mice
5. Effects of a fragment of human growth hormone-releasing factor in normal and 'little' mice
6. Receptor-associated resistance to growth hormone-releasing factor in dwarf 'little' mice
7. Histopathology of the pituitary gland in neonatal little (lit) mutant mice
8. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function
9. Molecular basis of the little mouse phenotype and implications for cell type-specific growth
10. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse
11. The dwarfs of Sindh: Severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene
12. Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene
13. Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene
14. G protein-coupled receptor family B, in the G protein-coupled receptor database
15. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors
16. The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain
17. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP
18. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination
19. Glucagon.glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding
20. Role of cysteine residues in the N-terminal extracellular domain of the human VIP 1 receptor for ligand binding. A site-directed mutagenesis study
21. Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding
22. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity
23. Localization of the domains involved in ligand binding and activaton of the glucose-dependent insulinotropic polypeptide receptor
24. Idenfification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins
25. Investigation of growth hormone releasing hormone receptor structure and activity using yeast expression technologies
26. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone
27. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone
28. Photoaffinity cross-linking to the pituitary receptor for growth hormone-releasing factor
29. Epitope tagging and protein surveillance
30. A short polypeptide marker sequence useful for recombinant protein identification and purification
31. Use of a hybrid vaccina virus-T7 RNA polymerase system for expression of target genes
32. Lipofection reagents prepared by a simple ethanol injection technique
33. Ligand: A versatile computerized approach for characterization of ligand-binding systems
34. Intracellular retention of mutant gonadotropin receptors results in loss of hormone binding activity of the follitropin receptor but not of the lutropin/choriogonadotropin receptor
35. Growth hormone-releasing hormone: Synthesis and signaling
36. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins
37. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: Analysis of expression, processing, and function
38. Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding
39. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system
40. Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus
41. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes
42. The effect of eight V2 vasopressin receptor mutations on stimulation of adenylyl cyclase and binding to vasopressin
43. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Bloomstrand chondryoplasia
44. Cloning and characterization of mouse growth hormone-releasing hormone (GRH) complementary DNA: Increased GRH messenger RNA levels in the growth hormone-deficient lit/lit mouse
45. Mouse growth-hormone-releasing hormone: Precursor structure and expression in brain and placenta
46. Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues
47. Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth
48. The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin). Specificities and identity
49. The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide
50. Synthesis and expression of a gene for the rat glucagon receptor. Replacement of an aspartic acid in the extracellular domain prevents glucagon binding